| Title |
Molecular targets of curcumin for cancer therapy: an updated review
|
|---|---|
| Published in |
Tumor Biology, July 2016
|
| DOI | 10.1007/s13277-016-5183-y |
| Pubmed ID | |
| Authors |
Pandima Devi Kasi, Rajavel Tamilselvam, Krystyna Skalicka-Woźniak, Seyed Fazel Nabavi, Maria Daglia, Anupam Bishayee, Hamidreza Pazoki-toroudi, Seyed Mohammad Nabavi |
| Abstract |
In recent years, natural edible products have been found to be important therapeutic agents for the treatment of chronic human diseases including cancer, cardiovascular disease, and neurodegeneration. Curcumin is a well-known diarylheptanoid constituent of turmeric which possesses anticancer effects under both pre-clinical and clinical conditions. Moreover, it is well known that the anticancer effects of curcumin are primarily due to the activation of apoptotic pathways in the cancer cells as well as inhibition of tumor microenvironments like inflammation, angiogenesis, and tumor metastasis. In particular, extensive studies have demonstrated that curcumin targets numerous therapeutically important cancer signaling pathways such as p53, Ras, PI3K, AKT, Wnt-β catenin, mTOR and so on. Clinical studies also suggested that either curcumin alone or as combination with other drugs possess promising anticancer effect in cancer patients without causing any adverse effects. In this article, we critically review the available scientific evidence on the molecular targets of curcumin for the treatment of different types of cancer. In addition, we also discuss its chemistry, sources, bioavailability, and future research directions. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 182 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | <1% |
| Unknown | 181 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 35 | 19% |
| Student > Bachelor | 16 | 9% |
| Student > Ph. D. Student | 15 | 8% |
| Student > Doctoral Student | 15 | 8% |
| Researcher | 14 | 8% |
| Other | 36 | 20% |
| Unknown | 51 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 35 | 19% |
| Pharmacology, Toxicology and Pharmaceutical Science | 21 | 12% |
| Medicine and Dentistry | 18 | 10% |
| Agricultural and Biological Sciences | 16 | 9% |
| Chemistry | 13 | 7% |
| Other | 22 | 12% |
| Unknown | 57 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 July 2016.
All research outputs
#18,466,751
of 22,881,964 outputs
Outputs from Tumor Biology
#1,370
of 2,623 outputs
Outputs of similar age
#282,201
of 365,664 outputs
Outputs of similar age from Tumor Biology
#36
of 97 outputs
Altmetric has tracked 22,881,964 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,623 research outputs from this source. They receive a mean Attention Score of 2.3. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 365,664 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 97 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.